Evidence map›Paper›PMID 29670074›Full record

ArticleThe American journal of case reports2018

Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor.

Hideyuki Yoshizumi, Tetsushi Ejima, Tetsuhiko Nagao, Masanori Wakisaka

Registry-linked trialAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04215445 (Effect of Sodium Glucose co Transporter 2), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04215445 phase4unknown statusstarted 2019, after this paper: background citation

Effect of Sodium Glucose co Transporter 2 (SGLT2) Inhibition on Optical Coherence Tomography Angiography (OCT-A) Parameters in Diabetic Chronic Kidney Disease (CKD)

Ran2019Enrolled90Registered outcomes3Posted comparisons0ConditionsChronic Kidney Diseases, Diabetes Mellitus, Diabetic RetinopathyArmsempagliflozin 25 mg, OCT-A
PMID 23042029PMID 25470017PMID 28340010PMID 29222381PMID 29363532PMID 29496507PMID 29501263PMID 30092018PMID 30123844PMID 30167660PMID 30510234PMID 12028457other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Current Treatments for Diabetic Macular Edema.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
  10. Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022
    Review
  11. Review
  12. Review
  13. The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy.Journal of diabetes research · 2020 · on this map
    Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hideyuki YoshizumiDepartment of Metabolism and Endocrinology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka City, Fukuoka, Japan.
Tetsushi EjimaFukuda Ophthalmological Hospital, Fukuoka City, Fukuoka, Japan.
Tetsuhiko NagaoSeiai Rehabilitation Hospital, Fukuoka City, Fukuoka, Japan.
Masanori WakisakaWakisaka Internal Medicine Clinic, Fukuoka City, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Diabetic macular edema (DME) causes serious visual impairments in diabetic patients. The standard treatments of DME are intra-vitreous injections of corticosteroids or anti-vascular endothelial growth factor antibodies and pan-photocoagulation. These treatments are unsatisfactory in their effects and impose considerable physical and economic burdens on the patients. CASE REPORT A 63-year-old woman was diagnosed as type 2 diabetes with retinopathy 7 years ago. Before the initiation of an SGLT2 inhibitor, the dipeptidyl peptidase-4 inhibitor, sitagliptin (50 mg daily), and metformin (250 mg dai- ly) were used for her glycemic control. The level of her hemoglobin A1c had been controlled around 7%. She began to feel decreased visual acuity and blurred vision of her left eye 8 months before the visit to our clin- ic. She was diagnosed as DME, which turned out to be corticosteroid-resistant. Her visual acuity further de- creased to 20/50. Metformin was changed to ipraglifl (25mg/day). Her left visual acuity started to improve after 4 weeks of treatment with ipragliflozin and improved to 20/22 after 24 weeks. The macular edema did not change until 12 weeks of the treatment, however, it decreased prominently after 16 weeks. CONCLUSIONS In our patient with steroid-resistant DME, her visual symptoms and macular edema recovered after the initiation of an SGLT2 inhibitor. SGLT2 inhibitors might be a potential candidate for the DME treatment.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleHumansHypoglycemic AgentsMacular EdemaMetforminMiddle AgedSitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsMetforminSitagliptin Phosphate

Identifiers

PMID29670074
PMCPMC5928754

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.